Brief: Galera Announces First Patient Dosed With GC4711 In Phase 2B Greco-2 Trial In Patients With Pancreatic Cancer
17/05/2021 12:12
May 17 (Reuters) - Galera Therapeutics Inc GRTX.O :
* GALERA ANNOUNCES FIRST PATIENT DOSED WITH GC4711 IN PHASE
2B
GRECO-2 TRIAL IN PATIENTS WITH PANCREATIC CANCER
Source text for Eikon: ID:nGNXbdLT3m
Further company coverage: GRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galera Therapeutics
See all newsBrief: Galera Therapeutics Says Nasdaq Will Delist Co's Common Stock By Filing Form 25 With SEC On Sept 4
Brief: Galera Announces Board Approval Of Complete Liquidation And Dissolution
Brief: Galera Therapeutics Receives Written Notice From Nasdaq Indicating That Nasdaq Hearings Panel Determined To Delist Co’s Shares
Brief: Alpha Pharma Investments Llc Reports 10.899% Passive Stake In Galera Therapeutics
Brief: Galera Adopts Limited Duration Stockholder Rights Agreement